ERBB2 and neoplasm: Regarding medical factors, Charlson/Deyo comorbidity score (for 3 vs 0, HR 2.36, 95% CI 2.10–2.67, P < 0.001; for 2 vs 0, HR 1.88, 95% CI 1.72–2.05, P < 0.001; for 1 vs 0, HR 1.42, 95% CI 1.34–1.51, P < 0.001), TNM disease stage (for III vs I, HR 2.60, 95% CI 2.44–2.78, P < 0.001; for II vs I, HR 1.66, 95% CI 1.56–1.76, P < 0.001), and tumor subtype (for HER2+ vs Luminal A/B, HR 1.19, 95% CI 1.12–1.28, P < 0.001; for triple-negative vs Luminal A/B, HR 1.76, 95% CI 1.64–1.89, P < 0.001) were significant.